keyword
MENU ▼
Read by QxMD icon Read
search

raltegravir

keyword
https://www.readbyqxmd.com/read/29318459/incidence-and-predictors-of-single-drug-discontinuation-according-to-the-presence-of-hcv-coinfection-in-hiv-patients-from-the-icona-foundation-cohort-study
#1
Sebastiano Leone, Milensu Shanyinde, Alessandro Cozzi Lepri, Fiona C Lampe, Pietro Caramello, Andrea Costantini, Andrea Giacometti, Andrea De Luca, Antonella Cingolani, Francesca Ceccherini Silberstein, Massimo Puoti, Andrea Gori, Antonella d'Arminio Monforte
To evaluate incidence rates of and predictors for any antiretroviral (ART) drug discontinuation by HCV infection status in a large Italian cohort of HIV infected patients. All patients enrolled in ICONA who started combination antiretroviral therapy (cART) containing abacavir or tenofovir or emtricitabine or lamivudine plus efavirenz or rilpivirine or atazanavir/r or darunavir/r (DRV/r) or lopinavir/r or dolutegravir or elvitegravir or raltegravir were included. Multivariate Poisson regression models were used to determine factors independently associated with single ART drug discontinuation...
January 9, 2018: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/29315113/integrase-resistance-associated-mutations-on-raltegravir-failure-in-western-india-a-preliminary-analysis
#2
Pujari Sanjay, Gaikwad S, Joshi K, Dabhade D, Sane S, Rao N, Bele V
No abstract text is available yet for this article.
January 8, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29304821/impact-of-the-hiv-1-genetic-background-and-hiv-1-population-size-on-the-evolution-of-raltegravir-resistance
#3
Axel Fun, Thomas Leitner, Linos Vandekerckhove, Martin Däumer, Alexander Thielen, Bernd Buchholz, Andy I M Hoepelman, Elizabeth H Gisolf, Pauline J Schipper, Annemarie M J Wensing, Monique Nijhuis
BACKGROUND: Emergence of resistance against integrase inhibitor raltegravir in human immunodeficiency virus type 1 (HIV-1) patients is generally associated with selection of one of three signature mutations: Y143C/R, Q148K/H/R or N155H, representing three distinct resistance pathways. The mechanisms that drive selection of a specific pathway are still poorly understood. We investigated the impact of the HIV-1 genetic background and population dynamics on the emergence of raltegravir resistance...
January 5, 2018: Retrovirology
https://www.readbyqxmd.com/read/29239896/ex-vivo-antiretroviral-potency-of-newer-integrase-strand-transfer-inhibitors-cabotegravir-and-bictegravir-in-hiv-1-non-b-subtypes
#4
Ujjwal Neogi, Kamlendra Singh, Shambhu G Aralaguppe, Leonard C Rogers, Duncan T Njenda, Stefan G Sarafianos, Bo Hejdeman, Anders Sönnerborg
OBJECTIVE: To determine the antiretroviral activity of the integrase strand transfer inhibitors (INSTIs), raltegravir, elvitegravir, dolutegravir, cabotegravir and bictegravir, against different subtypes as well as primary and acquired drug resistance mutations (DRM) in a patient-cohort infected with diverse subtypes. DESIGN: Biochemical and virological drug sensitivity analysis using patient derived HIV-1 genes and cross-sectional/longitudinal clinical study. METHODS: Assays for inhibition of 3'-end processing (IC50-3P), strand transfer (IC50-ST) and drug sensitivity (DSA) for five INSTIs were done using patient-derived integrase or gag-pol genes from subtypes A1, B, C, 01_AE and 02_AG...
December 12, 2017: AIDS
https://www.readbyqxmd.com/read/29239232/effectiveness-of-single-and-multiple-tablet-antiretroviral-regimens-in-correctional-setting-for-treatment-experienced-hiv-patients
#5
Andrew Merker, Melissa Badowski, Thomas Chiampas, Sarah E Pérez, Mahesh Patel, Jeremy Young, Ryan Werner
Minimal information is available regarding antiretroviral prescribing patterns and outcomes for HIV patients in correctional systems. This study analyzes single- (STR) and multiple- (MTR) tablet regimen effectiveness in patients receiving HIV telemedicine care through the Illinois Department of Corrections (IDOC). This study involves a retrospective review of HIV-positive adult patients in IDOC on either an STR (efavirenz, rilpivirine, elvitegravir based) or an MTR (emtricitabine/tenofovir with atazanavir/ritonavir, darunavir/ritonavir, or raltegravir)...
January 1, 2017: Journal of Correctional Health Care
https://www.readbyqxmd.com/read/29210661/impact-of-different-antiretroviral-strategies-on-total-hiv-dna-level-in-virologically-suppressed-hiv-1-infected-patients
#6
Isabella Bon, Leonardo Calza, Giuseppina Musumeci, Serena Longo, Alessia Bertoldi, Vanessa D'Urbano, Davide Gibellini, Eleonora Magistrelli, Pier Luigi Viale, Maria Carla Re
Background Total HIV-DNA load in peripheral blood cell (PBMCs) reflects the global viral reservoir that seems to be not affect by antiretroviral treatment. However, some studies reported a different permeability of different drugs in cellular compartments. Objective To investigate the relation between the amount of total HIV-1 DNA and different treatment strategies. Method Total HIV-1 DNA was quantified by real time PCR in PBMCs collected from 161 patients with long-term undetectable HIV-RNA receiving different therapy schedules (3-drug regimens or 2-drug regimen containing Raltegravir as integrase inhibitor)...
December 6, 2017: Current HIV Research
https://www.readbyqxmd.com/read/29210626/short-term-cost-and-efficiency-analysis-of-raltegravir-versus-atazanavir-ritonavir-or-darunavir-ritonavir-for-treatment-naive-adults-with-hiv-1-infection-in-spain
#7
Ashley E Davis, Anita J Brogan, Bridgett Goodwin, Gonzalo Nocea, Virginia Lozano
INTRODUCTION: The AIDS Clinical Trial Group (ACTG) 5257 clinical trial showed that raltegravir (RAL) was superior to atazanavir/ritonavir (ATV/r) and darunavir/ritonavir (DRV/r), when used in combination with emtricitabine/tenofovir DF (FTC/TDF), in a 96-week composite endpoint combining virologic efficacy and tolerability for treatment-naive adults with HIV-1 infection. This study aimed to estimate the efficiency associated with these three regimens in Spain. METHODS: An economic model was developed to estimate costs for antiretroviral drugs, adverse event management, and HIV care for individuals initiating first-line therapy...
November 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/29210076/in-vitro-effect-of-antiretroviral-drugs-on-cultured-primary-astrocytes-analysis-of-neurotoxicity-and-matrix-metalloproteinase-inhibition
#8
Tiziana Latronico, Ilaria Pati, Rossana Ciavarella, Anna Fasano, Fabio Mengoni, Miriam Lichtner, Vincenzo Vullo, Claudio Maria Mastroianni, Grazia Maria Liuzzi
There is little information available on the possible toxic effects that antiretroviral (ARV) drugs used for the treatment of human immunodeficiency virus (HIV)-infected subjects, may have on the central nervous system (CNS) resident cells. Moreover, it is unclear whether the efficacy of the ARV drugs may also be due to their ability to exert extravirological effects on factors responsible for the development of HIV brain injury, e.g. matrix metalloproteinases (MMPs). This study investigates the toxicity of three different ARV drugs and on their ability to modulate levels and expression of gelatinases A (MMP-2) and B (MMP-9) in astrocytes...
December 6, 2017: Journal of Neurochemistry
https://www.readbyqxmd.com/read/29199485/a-safety-evaluation-of-raltegravir-for-the-treatment-of-hiv
#9
Rosa de Miguel, Rocio Montejano, Natalia Stella-Ascariz, Jose R Arribas
Raltegravir (RAL) was the first commercialized agent from a new drug class with an innovative target, the integrase. Since its introduction in clinical practice RAL has become widely used for the treatment of HIV-1 infected patients. A decade after its approval, this article reviews key evidence from RAL with a special interest on safety outcomes. Areas covered: Pharmacologic, safety and efficacy data of RAL from clinical trials and post-commercialization published reports are hereby summarized after a literature review including PubMed search, relating proceedings and abstracts from relevant international HIV conferences, assessment reports from European and United States regulatory agencies and treatment guidelines (World Health Organization, United States Department of Health and Human Services and European AIDS Clinical Society), up to October 2017...
December 5, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29183270/results-from-the-post-exposure-prophylaxis-pilot-program-p-quad-demonstration-project-in-los-angeles-county
#10
Matthew R Beymer, Ryan M Kofron, Chi-Hong Tseng, Robert K Bolan, Risa P Flynn, Jennifer M Sayles, Mario J Perez, Wilbert C Jordan, Raphael J Landovitz
Post-exposure prophylaxis (PEP) is a promising but under-utilized strategy for HIV prevention in high-risk populations. Between March 2010 and June 2011, two community-based clinics in Los Angeles County provided PEP in a pilot program to 267 unique individuals. Courses were primarily dispensed to men who have sex with men (84%) and consisted overwhelmingly of a three-drug antiretroviral therapy regimen containing two nucleoside reverse transcriptase inhibitors and either an integrase inhibitor (raltegravir) or a boosted protease inhibitor (lopinavir/ritonavir)...
January 1, 2017: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/29145807/durability-of-switch-regimens-based-on-rilpivirine-or-on-integrase-inhibitors-both-in-association-with-tenofovir-and-emtricitabine-in-hiv-infected-virologically-suppressed-patients
#11
Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in virologically suppressed, HIV-infected patients. METHODS: Retrospective analysis of patients who started rilpivirine or an InSTI (both with tenofovir and emtricitabine) with <50 HIV-RNA copies/mL and had at least one HIV-RNA assessed while receiving the study regimen...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29140932/characteristics-of-treatment-experienced-hiv-infected-african-children-and-adolescents-initiating-darunavir-and-or-etravirine-based-antiretroviral-treatment
#12
Bethany Corrigan, Irene Mukui, Lloyd Mulenga, Nobuhle Mthethwa, Mosilinyane Letsie, Stephanie Bruno, Natella Rakhmanina
BACKGROUND: Data are limited on the selection and sequencing of second and third-line pediatric antiretroviral treatment (ART) in resource-limited settings. This study aimed to evaluate characteristics of African pediatric patients initiated on darunavir (DRV) and/or etravirine (ETR) through a specific drug donation program. METHODS: This was a cross-sectional study of baseline immunologic, virologic and demographic characteristics of children and adolescents initiating DRV- and/or ETR-based ART...
November 14, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29112076/virologic-suppression-and-cd4-cell-count-recovery-after-initiation-of-raltegravir-or-efavirenz-containing-hiv-treatment-regimens
#13
Jessie K Edwards, Stephen R Cole, H Irene Hall, W Christopher Mathews, Richard D Moore, Michael J Mugavero, Joseph J Eron
OBJECTIVE: To explore the effectiveness of raltegravir-based antiretroviral therapy (ART) on treatment response among ART-naive patients seeking routine clinical care. DESIGN: Cohort study of adults enrolled in HIV care in the United States. METHODS: We compared virologic suppression and CD4 cell count recovery over a 2.5 year period after initiation of an ART regimen containing raltegravir or efavirenz using observational data from a US clinical cohort, generalized to the US population of people with diagnosed HIV...
January 14, 2018: AIDS
https://www.readbyqxmd.com/read/29108797/lopinavir-plus-nucleoside-reverse-transcriptase-inhibitors-lopinavir-plus-raltegravir-or-lopinavir-monotherapy-for-second-line-treatment-of-hiv-earnest-144-week-follow-up-results-from-a-randomised-controlled-trial
#14
James G Hakim, Jennifer Thompson, Cissy Kityo, Anne Hoppe, Andrew Kambugu, Joep J van Oosterhout, Abbas Lugemwa, Abraham Siika, Raymond Mwebaze, Aggrey Mweemba, George Abongomera, Margaret J Thomason, Philippa Easterbrook, Peter Mugyenyi, A Sarah Walker, Nicholas I Paton
BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings...
November 3, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29106584/plasma-trough-concentrations-of-antiretrovirals-in-hiv-infected-persons-treated-with-direct-acting-antiviral-agents-for-hepatitis-c-in-the-real-world
#15
Massimo Tempestilli, Gabriele Fabbri, Ilaria Mastrorosa, Laura Timelli, Stefania Notari, Rita Bellagamba, Raffaella Libertone, Federico Lupi, Mauro Zaccarelli, Andrea Antinori, Chiara Agrati, Adriana Ammassari
Background: Possible drug-drug interactions (DDIs) between antiretrovirals (ARVs) and direct-acting antiviral agents (DAAs) are of some concern. Objectives: To investigate ARV plasma trough concentrations (Ctrough) before and during DAAs in patients treated in the real world. Methods: Single-centre, prospective, observational study including HIV/HCV coinfected persons undergoing DAA treatment. Self-reported adherence was assessed and ARVs Ctrough measured by HPLC-UV...
November 2, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29098203/prospective-analysis-of-lipid-composition-changes-with-antiretroviral-therapy-and-immune-activation-in-persons-living-with-hiv
#16
Martha A Belury, Emily Bowman, Janelle Gabriel, Brandon Snyder, Manjusha Kulkarni, Marilly Palettas, Xiaokui Mo, Jordan E Lake, David Zidar, Scott F Sieg, Benigno Rodriguez, Martin P Playford, Adriana Andrade, Daniel R Kuritzkes, Nehal N Mehta, Michael M Lederman, Nicholas T Funderburg
Background: Lipid profiles are altered by HIV infection and antiretroviral therapy (ART). Among HIV-uninfected (HIV-) populations the concentrations of various lipid classes (ie, lyso-phosphatidylcholine, LPC) and their saturated (SaFA), mono-unsaturated (MUFA), and polyunsaturated fatty acid (PUFA) composition are related to cardiometabolic disease risk. Associations between changes in the lipidome and immune activation in HIV-infected (HIV+) individuals beginning ART have not been described...
2017: Pathogens & Immunity
https://www.readbyqxmd.com/read/29082041/ritonavir-boosted-darunavir-plus-two-nucleoside-reverse-transcriptase-inhibitors-versus-other-regimens-for-initial-antiretroviral-therapy-for-people-with-hiv-infection-a-systematic-review
#17
REVIEW
Tatevik Balayan, Hacsi Horvath, George W Rutherford
BACKGROUND: Darunavir is a second-generation protease-inhibitor used with ritonavir (DRV/r) and two nucleoside reverse-transcriptase inhibitors as an option in first-line antiretroviral treatment (ART). METHODS: We systematically reviewed randomized controlled trials (RCTs) of DRV/r versus other regimens in patients initiating ART. We searched five bibliographic databases and other key resources. We had no language limitations. We assessed bias risk with the Cochrane tool and used GRADE to assess evidence quality...
2017: AIDS Research and Treatment
https://www.readbyqxmd.com/read/29077949/incorporation-of-aptamers-in-the-terminal-loop-of-shrnas-yields-an-effective-and-novel-combinatorial-targeting-strategy
#18
Ka Ming Pang, Daniela Castanotto, Haitang Li, Lisa Scherer, John J Rossi
Gene therapy by engineering patient's own blood cells to confer HIV resistance can potentially lead to a functional cure for AIDS. Toward this goal, we have previously developed an anti-HIV lentivirus vector that deploys a combination of shRNA, ribozyme and RNA decoy. To further improve this therapeutic vector against viral escape, we sought an additional reagent to target HIV integrase. Here, we report the development of a new strategy for selection and expression of aptamer for gene therapy. We developed a SELEX protocol (multi-tag SELEX) for selecting RNA aptamers against proteins with low solubility or stability, such as integrase...
October 25, 2017: Nucleic Acids Research
https://www.readbyqxmd.com/read/29077766/peripheral-blood-hiv-1-dna-dynamics-in-antiretroviral-treated-hiv-hcv-co-infected-patients-receiving-directly-acting-antivirals
#19
Gabriella Rozera, Gabriele Fabbri, Patrizia Lorenzini, Ilaria Mastrorosa, Laura Timelli, Mauro Zaccarelli, Alessandra Amendola, Alessandra Vergori, Maria Maddalena Plazzi, Stefania Cicalini, Andrea Antinori, Maria Rosaria Capobianchi, Isabella Abbate, Adriana Ammassari
BACKGROUND: Aim was to determine the dynamics of peripheral blood mononuclear cells (PBMC)- associated total HIV-1 DNA in successfully ART-treated HIV/HCV co-infected patients receiving DAA treatment and to explore possible virological hypotheses underlying the phenomenon. METHODS: Longitudinal, single-centre study measuring total HIV-1 DNA before the start of DAA, at the end of treatment (EOT), and 3 months after treatment. Univariable and multivariable analyses were used to assess factors associated with HIV-1 DNA increase ≥0...
2017: PloS One
https://www.readbyqxmd.com/read/29071467/raltegravir-once-daily-tablet-a-review-in-hiv-1-infection
#20
Emma D Deeks
A once-daily tablet formulation (Isentress® HD; Isentress® 600 mg) of the integrase strand transfer inhibitor raltegravir is now available for the treatment of HIV-1 infection. The 600 mg tablet has improved bioavailability versus the existing twice-daily 400 mg tablet (due, at least in part, to differences in tablet dissolution) and the recommended dosage is 1200 mg (i.e. two 600 mg tablets) once daily. In combination with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve adults, once-daily raltegravir 1200 mg provided virological suppression non-inferior to that seen with twice-daily raltegravir 400 mg over 48 and 96 weeks in the phase 3 ONCEMRK trial...
October 2017: Drugs
keyword
keyword
114249
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"